DGCI nod to Covaxin for use in children above 12 years with certain conditions

Tribune Web Desk

Updated At : 02:59 AM Dec 26, 2021 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

New Delhi, December 25

The Drugs Controller General of India (DCGI) has granted emergency use authorisation to Bharat Biotech’s Covaxin for children above 12 years with certain conditions, sources said on Saturday.

The Subject Expert Committee on COVID-19 of the CDSCO on October 12 after deliberating Bharat Biotech’s EUA application had recommended granting emergency use approval to Covaxin for use in the 12-18 years age group with certain conditions.

“The recommendations of the SEC were evaluated by another experts committee after which DCGI had sought additional data from the firm,” a source said.

The DCGI gave its approval Friday, the source said.

— PTI

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles